Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M183Revenue $M0Net Margin (%)0Z-Score
Enterprise Value $M183EPS $0Operating Margin %0F-Score0
P/E(ttm))0Cash Flow Per Share $0Pre-tax Margin (%)0Higher ROA y-yN
Price/Book010-y EBITDA Growth Rate %0Quick Ratio0Cash flow > EarningsN
Price/Sales05-y EBITDA Growth Rate %0Current Ratio0Lower Leverage y-yN
Price/Cash Flow0y-y EBITDA Growth Rate %ROA % (ttm)0Higher Current Ratio y-yN
Dividend Yield %0.8Insider Buy (3m)0ROE % (ttm)0Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M0ROI % (ttm)0Gross Margin Increase y-yN

Gurus Latest Trades with IHE

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found!

IHE is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


IHE: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Robson, Philip SpencerDirector or Senior Officer of Insider or Subsidiar 2014-12-19Buy5,000$0.8119058.02view
GOODALL, ROBERTDirector, Senior Officer 2014-12-18Buy4,800$11.151291.75view
Worrall, LawrenceDirector 2014-12-18Sell5,000$122.9526.21view
DeMare, NickDirector 2014-12-18Buy90,000$0.011551700view
Mandatum Life Insurance Compan10% Security Holder 2014-12-18Sell16,942$0.4137748.78view
Hannasch, Brian PatrickDirector or Senior Officer of Insider or Subsidiar 2014-12-18Sell87,583$45.68239.71view
MacPhail, Keith A.J.Director, Senior Officer 2014-12-18Buy50,000$50000-99.69view
Leshchyshen, BobSenior Officer 2014-12-18Buy9,500$0.2659584.62view
Di Gennaro, EnzioSenior Officer 2014-12-18Buy200$12.951098.3view
Felderhof, G. WilliamDirector 2014-12-18Buy3,000$0.15103353.33view

Press Releases about IHE :

    Quarterly/Annual Reports about IHE:

      News about IHE:

      Articles On GuruFocus.com

      More From Other Websites
      Bio-Twitter Sentiment Favors European Orexigen Obesity Pill Approval Dec 17 2014
      Viekirax/Exviera vs. Harvoni: Clash of the Hep C Drugs 2015 Dec 16 2014
      The Zacks Analyst Blog Highlights: Actavis, Allergan, iShares U.S. Pharmaceuticals ETF, Market... Nov 19 2014
      Pharma ETFs in Focus on Allergan Takeover Deal Nov 18 2014
      Big Pharma Solid Q3 Earnings Put These ETFs in Focus Oct 30 2014
      Drug ETFs Attractive Buys On Pullback Oct 22 2014
      Some ETFs Saying a Salix Takeover Could be Afoot Oct 03 2014
      Pfizer, Actavis Rumor, Inversion Turn Attention to Pharma ETFs Sep 24 2014
      ETFs for Hedge Funds’ Favorite Pharma Stocks Aug 25 2014
      The Zacks Analyst Blog Highlights: Powershares Dynamic Pharmaceuticals ETF, SPDR S&P Pharmaceuticals... Aug 25 2014
      Pharma ETF Investing 101 Aug 21 2014
      Pharma ETFs in Focus on String of Earnings Beat Jul 30 2014
      Sector Performance Update - First Half 2014 Jul 22 2014
      Johnson & Johnson, Goldman Sachs Pushing These ETFs Upward Jul 15 2014
      Big Pharma Looks For New Models Jun 10 2014
      How Will Pfizer Treat These Healthcare ETFs? May 06 2014
      Johnson & Johnson: Why Top Funds Are Buying May 01 2014
      Merck (MRK) Earnings Beat Puts Healthcare ETFs in Focus Apr 30 2014
      Pharma ETFs: A Safe Haven from the Biotech Stock Slump? Apr 28 2014
      Investors Flee Once Hot Health Care ETFs Apr 28 2014

      Add Notes, Comments

      If you want to ask a question, or report a bug, please create a support ticket.

      User Comments

      No comment yet
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      Free 7-day Trial
      FEEDBACK